Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

R3530

Sigma-Aldrich

Rifabutin

>98% (HPLC), powder, antibiotic

Sinonimo/i:

Ansamycin, Ansatipine (Farmitalia), LM-427, Mycobutin (Farmitalia)

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C46H62N4O11
Numero CAS:
Peso molecolare:
847.00
Codice UNSPSC:
12352200
NACRES:
NA.77

product name

Rifabutin, >98% (HPLC), powder

Saggio

>98% (HPLC)

Forma fisica

powder

Condizioni di stoccaggio

protect from light

Solubilità

DMSO: >5 mg/mL

Spettro attività antibiotica

neoplastics

Modalità d’azione

enzyme | inhibits

Ideatore

Johnson & Johnson

Condizioni di spedizione

wet ice

Temperatura di conservazione

−20°C

InChI

1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,49,52-54H,16-19,21H2,1-11H3,(H,47,57)/b13-12+,20-15+,24-14-/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1
ATEBXHFBFRCZMA-VXTBVIBXSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Azioni biochim/fisiol

Rifabutin is an antibiotic; antitumor. Rifabutin interferes with HSP-90 molecular chaperone, enhances ubiquitination and protein degradation, and inactivates bacterial RNA polymerase.

Caratteristiche e vantaggi

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type N95 (US)


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 10

1 of 10

Rifaximin VETRANAL®, analytical standard

Supelco

33999

Rifaximin

Levofloxacin 98.0-102.0% anhydrous basis (HPLC)

Sigma-Aldrich

28266

Levofloxacin

Amikacin sulfate United States Pharmacopeia (USP) Reference Standard

USP

1019494

Amikacin sulfate

Rifampin United States Pharmacopeia (USP) Reference Standard

USP

1604009

Rifampin

Clofazimine

Sigma-Aldrich

C8895

Clofazimine

USP

USP

1019508

Amikacin

Marina Pinheiro et al.
Journal of medicinal chemistry, 56(2), 417-426 (2012-12-12)
This work focuses on the interaction of rifabutin (RFB), a naphthalenic ansamycin, with membrane models. Since the therapeutic and toxic effects of this class of drugs are strongly influenced by their lipid affinity, we concerned specifically on the ability of
Sivappa Rasapalli et al.
Organic letters, 15(7), 1736-1739 (2013-03-27)
A facile synthesis of the western segment of divergolides C and D has been developed. Exploratory studies with two disconnections, i.e., C4-C5 vs C5-C6, for elaboration of the ansa bridge to the sterically demanding hexasubstituted naphthalenic aromatic core using a
Frederick A Sirgel et al.
PloS one, 8(3), e59414-e59414 (2013-03-26)
Genetically related Mycobacterium tuberculosis strains with alterations at codon 516 in the rpoB gene were observed amongst a substantial number of patients with drug resistant tuberculosis in the Eastern Cape Province (ECP) of South Africa. Mutations at codon 516 are
Won-Jung Koh et al.
American journal of respiratory and critical care medicine, 186(8), 797-802 (2012-08-11)
Little is known regarding the application of therapeutic drug monitoring for treatment of Mycobacterium avium complex (MAC) lung disease. To evaluate drug interactions of multidrug regimens and clinical usefulness of therapeutic drug monitoring in the management of MAC lung disease.
Jakko van Ingen et al.
American journal of respiratory and critical care medicine, 186(6), 559-565 (2012-06-30)
Currently recommended multidrug treatment regimens for Mycobacterium avium complex (MAC) lung disease yield limited cure rates. This results, in part, from incomplete understanding of the pharmacokinetics and pharmacodynamics of the drugs. To study pharmacokinetics, pharmacodynamics, and drug interactions of multidrug

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.